In Japan, bevacizumab (Bev), a monoclonal antibody against the potent angiogenic factor, vascular endothelial growth factor (VEGF) has been approved for newly diagnosed and recurrent high-grade gliomas. This evidence concerns the gene VEGFA and glioma.